Register for free to
view the full innovation profile.
The invention is fast and easy cell-based assay and safe system, which can be done under Biosafety Level 2 guideline.
About
Invention Summary Background: Persistence of HIV-1 in latently infected CD4+ T-cells prevents eradication of virus in patients. The half-life of the latently infected population is quite long. To fully eliminate virus, small molecules that can reach and activate latent viral reservoirs could potentially be utilized to eliminate the latent arm of the infection by the combination with current antiretroviral therapy. Invention: This technology is a cell-based assay for high-throughput screening for novel compounds that can activate latent HIV-1. It provides an isolated, latently infected T cell line. Upon treatment with compounds, latent virus can be reactivated and detected by biomarkers. This invention measures both early (egfp) and late (SEAP expression) markers of HIV-1 re-activation via flow cytometry and chemiluminesence respectively. Besides, this technology utilized a latent provirus that was replication-incompetent. The screening can be done under Biosafety Level 2 labs. Therefore, this invention is more accessible and cheaper for facilities to adopt. Market Application Used for high-throughput screening for small molecules or compounds that can reactivate latency HIV-1 virus; Compounds identified can be combined with current HIV therapy to increase efficacy. Advantages • Fast and easy cell-based assay • Safe system, which can be done under Biosafety Level 2 guideline • Screening can be scaled up to 384-well